Human Disease Model Report: cancer, epithelial, RAF-SCRIB-related

General Information

Name

cancer, epithelial, RAF-SCRIB-related

FlyBase ID

FBhh0001079

Disease Ontology Term

carcinoma

Parent Disease

OMIM

Overview

A model of epithelial cancer has been developed using the loss-of-function mutations of the Drosophila scrib gene in combination with a constitutively active form of the Drosophila Raf gene, assayed in the developing eye. See also the human disease model reports 'cancer, epithelial, SCRIB-related' (FBhh0000587), 'cancer, multiple, RAF1-related' (FBhh0000558), and 'cancer, epithelial, RAS-SCRIB-related' (FBhh0000585).

When induced in the developing eye during the larval stage, scrib(-) clones result in small benign lesions in the adult eye that appear undifferentiated and disorganized. Clones induced in the developing eye that express activated Raf (Raf^UAS.F179) develop into vigorously proliferating tissue during larval stages and ultimately overgrow much of the adult eye. This tissue overgrowth remains restricted to the tissues derived from the eye-antennal disc and is apparently not invasive; the animals survive until pharate adult stages. When clones containing the activated Raf allele combined with a loss-of-function mutation for scrib are induced, massive and invasive overgrowth occurs in larval stages, which kills the animal before pupation. Combining an additional element, an activated form of hep which results in increased JNK signaling, significantly, but not completely, suppresses the aggressive overgrowth.

This disease model has been used to investigate the disruption of zinc homeostasis that has been observed for various cancers.

[updated Apr. 2021 by FlyBase; FBrf0222196]

Disease Summary Information

Disease Summary: cancer, epithelial, RAF-SCRIB-related

OMIM report

Human gene(s) implicated

Symptoms and phenotype

Genetics

Cellular phenotype and pathology

Molecular information

External links

COSMIC gene: SCRIB
COSMIC gene: RAF1
Gene2Function (human gene): RAF1
Gene2Function (human gene): SCRIB
Gene Cards: RAF1
Gene Cards: SCRIB
KEGG Disease Pathways: Pathways in Cancer
MARRVEL (human gene): RAF1
MARRVEL (human gene): SCRIB
NCBI (Entrez) gene: RAF1; Raf-1 proto-oncogene, serine/threonine kinase
NCBI (Entrez) gene: SCRIB; scribble planar cell polarity protein

Disease synonyms

Related Diseases

Related human health report(s)

cancer, epithelial, RAS-SCRIB-related

cancer, epithelial, SCRIB-related

cancer, multiple, RAF1-related

Ortholog Information

Human gene(s) in FlyBase

Other mammalian ortholog(s) used

D. melanogaster Gene Information (2)

Dmel\scrib

Gene Snapshot

scribble (scrib) encodes a scaffolding protein that is part of the conserved machinery regulating apicobasal polarity. It acts with the products of dlg1 and l(2)gl to distinguish the basolateral domain of epithelial cells and neuroblasts, via reciprocally antagonistic interactions with the aPKC/par-6 complex that impacts vesicle trafficking. The product of scrib also organizes synaptic architecture and is implicated in learning and memory. [Date last reviewed: 2019-03-14]

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

SCRIBC

Comments on ortholog(s)

Ortholog of human SCRIB and LRRC1 (1 Drosophila to 2 human); Dmel\scrib shares 33% identity and 45% similarity with the human SCRIB gene. The human LRRC1 gene encodes a much smaller protein, corresponding to the amino end of SCRIB and Dmel\scrib; it shares 57% identity and 73% similarity with Dmel\scrib within that extent.

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\Raf

Gene Snapshot

Raf oncogene (Raf) encodes a serine-threonine protein kinase that acts downstream of the product of Ras85D. It activates the MEK/ERK pathway to regulate cell proliferation, differentiation and survival downstream of receptor tyrosine kinases such as those encoded by tor, Egfr, and sev. [Date last reviewed: 2019-03-14]

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

High-scoring ortholog of human RAF1, BRAF, and ARAF (1 Drosophila to 3 human); Dmel\Raf shares 43-47% identity and 56-60% similarity with the human genes.

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Other Genes Used: Viral, Bacterial, Synthetic (0)

Summary of Physical Interactions (105 groups)

scrib

protein-protein

Interacting group

Assay

References

scrib

anti tag coimmunoprecipitation, anti tag western blot

(Gui et al., 2016)

scrib - α-Cat

anti tag coimmunoprecipitation, anti tag western blot

(Huang et al., 2023)

scrib - bark

proximity ligation assay, fluorescence microscopy

(Sharifkhodaei et al., 2019)

scrib - dlg1

colocalization, fluorescence microscopy, inferred by author, anti tag coimmunoprecipitation, western blot, anti bait coimmunoprecipitation, proximity-dependent biotin identification, proximity ligation assay

(Sharp et al., 2021, Ventura et al., 2020, Nakajima et al., 2019, Sharifkhodaei et al., 2019, Rui et al., 2017, Mathew et al., 2002)

scrib - Gli

proximity ligation assay, fluorescence microscopy

(Sharifkhodaei et al., 2019)

scrib - gukh

anti bait coimmunoprecipitation, western blot, isothermal titration calorimetry, predetermined participant, x-ray crystallography

(Caria et al., 2018, Mathew et al., 2002)

scrib - Mad

anti tag coimmunoprecipitation, anti tag western blot

(Gui et al., 2016)

scrib - Nrx-1

anti tag coimmunoprecipitation, western blot, pull down

(Rui et al., 2017)

scrib - Pak

anti tag coimmunoprecipitation, western blot

(Bahri et al., 2010)

scrib - Pak3

anti tag coimmunoprecipitation, western blot

(Cervantes-Sandoval et al., 2016, Bahri et al., 2010)

scrib - Rab5

anti tag coimmunoprecipitation, anti tag western blot

(Gui et al., 2016)

scrib - Rac1

anti tag coimmunoprecipitation, western blot

(Cervantes-Sandoval et al., 2016)

scrib - tkv

anti tag coimmunoprecipitation, anti tag western blot

(Gui et al., 2016)

scrib - Traf4

pull down, autoradiography

(Mathew et al., 2011)

scrib - tsr

anti tag coimmunoprecipitation, western blot

(Cervantes-Sandoval et al., 2016)

scrib - Vang

pull down, autoradiography, two hybrid, anti tag coimmunoprecipitation, anti tag western blot

(Humphries et al., 2023, Courbard et al., 2009)

Raf

protein-protein

Interacting group

Assay

References

Raf - 14-3-3ε

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - 14-3-3ζ

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Act42A

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Aldh

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Apl

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Arc1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - AspRS-m

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - BCAS2

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - βCOP

anti tag coimmunoprecipitation, peptide massfingerprinting, anti tag western blot

(Friedman et al., 2011, Friedman et al., 2011)

Raf - βTub60D

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - βTub97EF

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - blanks

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CCT1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Cdc37

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CG3651

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CG6961

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CG8036

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CG9775

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CG11417

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CG11999

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CG13117

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CkIIα

enzymatic study, autoradiography

(Stark et al., 2011)

Raf - cnk

two hybrid, anti tag coimmunoprecipitation, western blot, peptide massfingerprinting

(Friedman et al., 2011, Therrien et al., 1998)

Raf - CSN8

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - CtsL1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Dlc90F

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - drk

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Dsor1

two hybrid, anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011, Therrien et al., 1998)

Raf - eEF2

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - eIF4A

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Eip63E

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - fmt

anti tag coimmunoprecipitation, anti tag western blot, peptide massfingerprinting

(Friedman et al., 2011, Friedman et al., 2011)

Raf - galla-2

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - GckIII

anti tag coimmunoprecipitation, anti tag western blot

(Friedman and Perrimon, 2006)

Raf - GCS2β

anti tag coimmunoprecipitation, anti tag western blot, peptide massfingerprinting

(Friedman et al., 2011, Friedman et al., 2011)

Raf - Gfat2

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Gyf

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Hrb87F

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Hsp60A

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Hsp70Ab

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Hsp83

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Ipo9

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Kcmf1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - krz

anti tag coimmunoprecipitation, anti tag western blot

(Tipping et al., 2010)

Raf - ksr

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Lk6

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Mcad

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - morgue

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - NAT1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - nesd

anti tag coimmunoprecipitation, anti tag western blot

(Friedman et al., 2011)

Raf - Nfs1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Nup50

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Past1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Pdha1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - PH4αEFB

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - pic

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - PpV

anti tag coimmunoprecipitation, peptide massfingerprinting, anti tag western blot

(Friedman et al., 2011, Friedman et al., 2011)

Raf - Psa

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Pyk

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Rack1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Rap1

anti tag coimmunoprecipitation, anti tag western blot, two hybrid

(Ding et al., 2010, Mishra et al., 2005)

Raf - Ras64B

pull down, autoradiography

(Vega-Cuesta et al., 2020, Yang and Terman, 2012)

Raf - Ras85D

pull down, two hybrid, anti tag coimmunoprecipitation, anti tag western blot

(Yang and Terman, 2012, Ding et al., 2010, Mishra et al., 2005)

Raf - rl

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpL3

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpL17

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpL27

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpL27A

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpL28

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpL35A

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Rpn1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpS15Aa

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpS18

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpS26

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - RpS27A

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Rpt1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Rpt5

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - ScsβA

anti tag coimmunoprecipitation, anti tag western blot

(Friedman et al., 2011)

Raf - SERCA

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - sesB

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - shv

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - sip2

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Slik

anti tag coimmunoprecipitation, anti tag western blot

(Hipfner and Cohen, 2003)

Raf - SPARC

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Ssb-c31a

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - TBPH

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - Tim23

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - wal

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Raf - yata

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Alleles Reported to Model Human Disease (Disease Ontology) (23 alleles)

scrib

Models Based on Experimental Evidence ( 10 )

Allele

Disease

Evidence

References

scrib^KK101128

model of cancer

CEA

(Tamori et al., 2016)

CEA with Stat92E^{ΔNΔC.UASp.Tag:HA}, RhoGEF2^HMS01118

(Tamori et al., 2016)

CEA with Ras85D^V12.UAS

(Muzzopappa et al., 2017)

model of leukemia

CEA with Ras85D^V12.UAS

(Arefin et al., 2017)

model of carcinoma

CEA with Ras85D^V12.UAS

(Murcia et al., 2019)

scrib^j7B3

model of cancer

CEA with Hsap\SCRIB^UAS.EGFP

(Dow et al., 2003)

CEA with Ras85D^V12.UAS

(Pagliarini and Xu, 2003)

scrib^GD11663

model of carcinoma

CEA

(Wu et al., 2021)

model of cancer

CEA

(Yang et al., 2022)

scrib⁶⁷³

model of carcinoma

CEA with scrib¹

(de Vreede et al., 2022)

CEA

(de Vreede et al., 2022, Brumby and Richardson, 2003, Bilder et al., 2000)

CEA with Ras85D^V12.UAS

(Amcheslavsky et al., 2018)

model of brain cancer

CEA with Ras85D^V12.cUa.UAS

(Manzanero-Ortiz et al., 2021)

model of cancer

CEA with Egfr^2.A887T.UAS

(Sheng and Du, 2020)

scrib^GD11666

model of cancer

CEA

(Ding et al., 2021)

model of carcinoma

CEA

(Ding et al., 2022, Sun et al., 2019, Zhang et al., 2019)

scrib¹

model of carcinoma

CEA

(Zheng et al., 2023, Kong et al., 2022, Kong et al., 2021, Parvy et al., 2019, Katsukawa et al., 2018, O'Keefe et al., 2015, Igaki et al., 2009, Uhlirova et al., 2005, Brumby and Richardson, 2003, Bilder et al., 2000)

CEA with scrib⁶⁷³

(de Vreede et al., 2022)

CEA with Ras85D^V12.UAS

(Kong et al., 2021, Mishra-Gorur et al., 2019, Srivastava et al., 2007, Igaki et al., 2006, Uhlirova and Bohmann, 2006)

CEA with Raf^UAS.F179

(Wei et al., 2021, Uhlirova et al., 2005)

CEA with egr¹

(Igaki et al., 2009)

CEA with Rab5^S43N.UAS

(Igaki et al., 2009)

model of cancer

CEA with Ras85D^V12.UAS

(Cong et al., 2021, Hodgson et al., 2021, Külshammer et al., 2015, Külshammer and Uhlirova, 2013, Willoughby et al., 2013, Wu et al., 2010, Pagliarini and Xu, 2003)

CEA with cno^R2

(Rives-Quinto et al., 2017)

CEA

(Sanaki et al., 2020, Bunker et al., 2015, Ohsawa et al., 2011)

CEA with rl^R80S.UAS

(Kushnir et al., 2020)

CEA with rl^{D334N.UAS.cKa}

(Kushnir et al., 2020)

CEA with rl^{R80S.D334N.UAS}

(Kushnir et al., 2020)

CEA with Ras85D^V12.QUAS.cHa

(Hodgson et al., 2021)

CEA with Ras85D^V12.cUa.UAS

(Yang et al., 2022, Khezri et al., 2021)

CEA with Raf^UAS.F179

(Yang et al., 2022)

model of benign neoplasm

CEA

(de Vreede et al., 2018)

model of kidney cancer

CEA

(Zeng et al., 2010)

scrib^HMS01490

model of cancer

CEA

(Bunker et al., 2015)

model of carcinoma

CEA

(Yadav and Srikrishna, 2019)

scrib^HMJ21977

model of carcinoma

CEA with yki^{S111A.S168A.S250A.UAS.Tag:V5}

(Snigdha et al., 2021)

CEA with Ras85D^V12.UAS

(Snigdha et al., 2021)

CEA

(Snigdha et al., 2021)

scrib^RNAi.UAS.cUa

model of carcinoma

CEA

(Song et al., 2023, Xu et al., 2022)

model of cancer

CEA with Ras85D^V12.UAS

(Hodgson et al., 2021)

scrib^{QUAS.HMS01490}

model of cancer

CEA with Ras85D^V12.QUAS.cLa

(Bakopoulos et al., 2023, Lodge et al., 2021)

Modifiers Based on Experimental Evidence ( 11 )

Allele

Disease

Interaction

References

scrib^KK101128

model of cancer

is exacerbated by Stat92E^{ΔNΔC.UASp.Tag:HA}

(Tamori et al., 2016)

scrib^j7B3

ameliorates viral infectious disease

modeled by EBV\BRLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

ameliorates infectious mononucleosis

modeled by EBV\BRLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

ameliorates Epstein-Barr virus hepatitis

modeled by EBV\BRLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

scrib^GD11663

model of carcinoma

is ameliorated by CtBP^HMS00677

(Wu et al., 2021)

is ameliorated by CtBP^JF01291

(Wu et al., 2021)

is ameliorated by puc^UAS.cMa

(Wu et al., 2021)

model of cancer

is ameliorated by Ire1^UAS.Tag:V5

(Yang et al., 2022)

is ameliorated by Xbp1^UAS.s.Tag:V5

(Yang et al., 2022)

scrib⁶⁷³

exacerbates brain cancer

modeled by Ras85D^V12.cUa.UAS, dlg1^GD4689

(Manzanero-Ortiz et al., 2021)

modeled by Ras85D^V12.cUa.UAS, l(2)gl^KK100777

(Manzanero-Ortiz et al., 2021)

modeled by Ras85D^V12.cUa.UAS, wts^KK101055

(Manzanero-Ortiz et al., 2021)

scrib^GD11666

model of cancer

is exacerbated by hpo^RNAi.UAS.cUa

(Ding et al., 2021)

is exacerbated by wts^RNAi.UAS.cUa

(Ding et al., 2021)

is ameliorated by yki^RNAi.UAS.cUa

(Ding et al., 2021)

model of carcinoma

is ameliorated by lic^GD7546

(Sun et al., 2019)

is ameliorated by lic^JF01433

(Sun et al., 2019)

is ameliorated by pan^JF02306

(Zhang et al., 2019)

is ameliorated by wg^GD5007

(Zhang et al., 2019)

is exacerbated by Toll-7^{C993Y.UAS.Tag:FLAG}

(Ding et al., 2022)

is ameliorated by Toll-7^GD14417

(Ding et al., 2022)

is ameliorated by Toll-7^HM05230

(Ding et al., 2022)

scrib¹

model of carcinoma

is exacerbated by α-Spec^HMC04371

(Kong et al., 2022)

is exacerbated by Rho1^72F

(Kong et al., 2022)

is exacerbated by Rok^GD1522

(Kong et al., 2022)

is exacerbated by Toll-6^GD14438

(Kong et al., 2022)

is exacerbated by Toll-6^GD35

(Kong et al., 2022)

is exacerbated by kst^GLC01654

(Kong et al., 2022)

is exacerbated by sqh^GL00663

(Kong et al., 2022)

is exacerbated by zip^GD1566

(Kong et al., 2022)

is exacerbated by BacA\p35^UAS.cHa

(Zheng et al., 2023, Brumby and Richardson, 2003)

is ameliorated by Dad^UAS.cTa

(Brumby and Richardson, 2003)

is ameliorated by Egfr^DN.UAS

(Brumby and Richardson, 2003)

is exacerbated by N^ICN.UAS

(Brumby and Richardson, 2003)

is exacerbated by Ras85D^V12.UAS

(Brumby and Richardson, 2003)

is exacerbated by bsk^K53R.UAS

(Uhlirova et al., 2005, Brumby and Richardson, 2003)

is ameliorated by pan^ΔN.UAS

(Brumby and Richardson, 2003)

is ameliorated by Wwox^KK108459

(O'Keefe et al., 2015)

is exacerbated by Dif^LA00958

(Katsukawa et al., 2018)

is ameliorated by Spn88Ea^GD12724

(Katsukawa et al., 2018)

is ameliorated by Spn88Ea^HMS01371

(Katsukawa et al., 2018)

is ameliorated by Spn88Ea^c01214

(Katsukawa et al., 2018)

is ameliorated by Spn88Ea^eld5

(Katsukawa et al., 2018)

is exacerbated by Tl^10b.UAS

(Katsukawa et al., 2018)

is exacerbated by dl^UAS.cHa

(Katsukawa et al., 2018)

is ameliorated by hep^Act.UAS

(Uhlirova et al., 2005)

is ameliorated by kay^RNAi.UAS

(Uhlirova and Bohmann, 2006)

is ameliorated by puc^UAS.cMa

(Uhlirova and Bohmann, 2006)

is exacerbated by Def^SK3

(Parvy et al., 2019)

is exacerbated by egr³

(Parvy et al., 2019)

is exacerbated by bsk^DN.UAS.cUa

(Kong et al., 2021)

is ameliorated by msn^UAS.cSa

(Kong et al., 2021)

is ameliorated by Diap1^UAS.cHa

(Zheng et al., 2023)

is ameliorated by Dronc^DN.UAS.cUa

(Zheng et al., 2023)

is ameliorated by Ire1^GD3071

(Zheng et al., 2023)

is ameliorated by Ire1^f02170

(Zheng et al., 2023)

is ameliorated by Xbp1^GD4745

(Zheng et al., 2023)

is ameliorated by Xbp1^UAS.s.Tag:V5

(Zheng et al., 2023)

is exacerbated by bsk^DN.UAS

(Zheng et al., 2023)

is ameliorated by HAdV-C\E4orf4^UAS.cPa

(Rosen et al., 2019)

is ameliorated by HAdV-C\E4orf4^UAS.cPb

(Rosen et al., 2019)

model of cancer

is ameliorated by hep^r75

(Bunker et al., 2015)

is ameliorated by yki^B5

(Bunker et al., 2015)

is ameliorated by egr¹

(Ohsawa et al., 2011)

is ameliorated by Ilp2¹

(Sanaki et al., 2020)

is exacerbated by Ilp2^UAS.cBa

(Sanaki et al., 2020)

is ameliorated by Ilp5³

(Sanaki et al., 2020)

is ameliorated by InR^K1409A.UAS

(Sanaki et al., 2020)

is exacerbated by InR^UAS.Exel

(Sanaki et al., 2020)

is exacerbated by chico¹

(Sanaki et al., 2020)

is exacerbated by chico^KK107581

(Sanaki et al., 2020)

scrib^HMS01490

model of cancer

is ameliorated by dome^ΔCYT.UAS

(Bunker et al., 2015)

is ameliorated by Socs36E^UASp.cCa

(Bunker et al., 2015)

model of carcinoma

is exacerbated by park^JF01200

(Yadav and Srikrishna, 2019)

is ameliorated by park^{UAS.Tag:FLAG,Tag:Mito(hCOX4I1)}

(Yadav and Srikrishna, 2019)

scrib^HMJ21977

model of carcinoma

is ameliorated by wgn^GLC01716

(Snigdha et al., 2021)

scrib^UASp.cRa

exacerbates tauopathy

modeled by Hsap\MAPT^UAS.cWa

(Feuillette et al., 2020)

scrib^RNAi.UAS.cUa

model of carcinoma

is exacerbated by apt^GD1367

(Song et al., 2023)

is ameliorated by apt^UAS.cEa

(Song et al., 2023)

is ameliorated by Gadd45^KK104250

(Xu et al., 2022)

is ameliorated by Glyat^TH00482

(Xu et al., 2022)

is ameliorated by Glyat^c02982

(Xu et al., 2022)

is ameliorated by Gadd45^HMS01436

(Xu et al., 2022)

scrib^UAS.GFP

ameliorates autism spectrum disorder

modeled by Nrx-1²⁷³

(Rui et al., 2017)

Raf

Models Based on Experimental Evidence ( 5 )

Allele

Disease

Evidence

References

Raf^F22.hs

model of cancer

CEA

(Zhao et al., 2021)

Raf^UAS.F179

model of cancer

CEA with RhoGEF2^RE.UAS

(Khoo et al., 2013)

CEA

(Ren et al., 2022, Lee et al., 2021, Pfeifle et al., 2019)

CEA with scrib¹

(Yang et al., 2022)

model of carcinoma

CEA with scrib¹

(Wei et al., 2021, Uhlirova et al., 2005)

Raf^RNAi.UAS.cUa

model of cardiomyopathy

CEA

(Yu et al., 2013)

Raf^{A572E.UAS.Tag:FLAG}

model of cancer

CEA

(Pfeifle et al., 2019)

Raf^CA.UAS.cUa

model of high grade glioma

CEA

(Xie et al., 2023)

Modifiers Based on Experimental Evidence ( 9 )

Allele

Disease

Interaction

References

Raf¹²

ameliorates neurofibromatosis

modeled by Nf1^E2

(Walker et al., 2006)

Raf⁷

ameliorates multiple endocrine neoplasia type 2B

modeled by Ret^MEN2B.UAS

(Sonoshita et al., 2018)

Raf^DN.UAS

ameliorates carcinoma

modeled by Ras85D^V12.UAS

(Zoranovic et al., 2018)

Raf^F22.hs

model of cancer

is ameliorated by slif^UY681

(Zhao et al., 2021)

is ameliorated by Atg1^HMS02750

(Zhao et al., 2021)

is exacerbated by Atg101^6h

(Zhao et al., 2021)

is ameliorated by Atg16^MI00187

(Zhao et al., 2021)

is ameliorated by Atg5^HMS01244

(Zhao et al., 2021)

is ameliorated by Atg6^HMS01483

(Zhao et al., 2021)

is ameliorated by Balat^HMC06377

(Zhao et al., 2021)

is ameliorated by CarT^HMC04919

(Zhao et al., 2021)

is ameliorated by Cat^UAS.cAa

(Zhao et al., 2021)

is ameliorated by bsk^HMS00777

(Zhao et al., 2021)

is ameliorated by bsk^K53R.UAS

(Zhao et al., 2021)

is ameliorated by slif^HMC05846

(Zhao et al., 2021)

Raf^UAS.F179

model of cancer

is ameliorated by Atg1^UAS.cSa

(Lee et al., 2021)

is ameliorated by dind^{RNAi.UAS.RNAi}

(Ren et al., 2022)

exacerbates gastrointestinal system cancer

modeled by Apc2^g10, Apc^Q8

(Wang et al., 2013)

exacerbates carcinoma

modeled by ft^k07918

(Garoia et al., 2005)

modeled by ft^G-rv

(Garoia et al., 2005)

model of carcinoma

is ameliorated by hep^Act.UAS

(Uhlirova et al., 2005)

Raf^XS-2541

ameliorates carcinoma

modeled by Ras85D^V12.UAS

(Karim and Rubin, 1998)

modeled by Ras85D^V12.ey

(Karim and Rubin, 1998)

Raf^GD9831

ameliorates Huntington's disease

modeled by @Huntington's??not a valid allele symbol??@, @disease??not a valid allele symbol??@

(Miller et al., 2012)

Raf^KK100982

ameliorates autosomal dominant cerebellar ataxia

modeled by Hsap\ATXN1^82Q.UAS

(Park et al., 2013)

Raf^CA.UAS.cUa

model of high grade glioma

is ameliorated by slo^HMC04093

(Xie et al., 2023)

is ameliorated by slo^JF02146

(Xie et al., 2023)

is ameliorated by slo^KO

(Xie et al., 2023)

is exacerbated by slo^UAS.cXa

(Xie et al., 2023)

Alleles Representing Disease-Implicated Variants

Genetic Tools, Stocks and Reagents

Sources of Stocks

Contact lab of origin for a reagent not available from a public stock center.

Bloomington Stock Center Disease Page

Related mammalian, viral, bacterial, or synthetic transgenes

Allele

Transgene

Publicly Available Stocks

Selected Drosophila transgenes

Allele

Transgene

Publicly Available Stocks

Raf^{A572E.UAS.Tag:FLAG}

P{UAS-Raf.A572E.FLAG}

w^*; P{UAS-Raf.gof}F179

Raf^F22.hs

P{Hsp70-Draf.gof}

w^*; P{Hsp70-Draf.gof}3/TM3, Sb¹

w^*; P{UASp-scrib.R}B10

RNAi constructs available

Allele

Transgene

Publicly Available Stocks

Raf^GD9831

P{GD9831}

w¹¹¹⁸; P{GD9831}v20909

y¹ v¹; P{TRiP.JF01185}attP2

Raf^JF01483

P{TRiP.JF01483}

y¹ v¹; P{TRiP.JF01483}attP2

y¹ v¹; P{TRiP.GL01125}attP40

Raf^HMC03854

P{TRiP.HMC03854}

y¹ sc^* v¹ sev²¹; P{TRiP.HMC03854}attP2

Raf^HMC04133

P{TRiP.HMC04133}

y¹ v¹; P{TRiP.HMC04133}attP2

scrib^RNAi.UAS.cUa

P{UAS-scrib.RNAi.U}

scrib^{QUAS.HMS01490}

PBac{QUAS-HMS01490}

scrib^{RNAi.13xlexAop.cZa}

P{13xlexAop-scrib.RNAi.Z}

scrib^GD11666

P{GD11666}

w¹¹¹⁸ P{GD11666}v27430

y¹ v¹; P{TRiP.JF03229}attP2

scrib^HMS01490

P{TRiP.HMS01490}

y¹ sc^* v¹ sev²¹; P{TRiP.HMS01490}attP2

y¹ sc^* v¹ sev²¹; P{TRiP.GL00638}attP40

scrib^HMS01993

P{TRiP.HMS01993}

y¹ sc^* v¹ sev²¹; P{TRiP.HMS01993}attP40/CyO

y¹ v¹; P{TRiP.HMJ21977}attP40/CyO

scrib^RNAi.UAS

P{UAS-scrib.RNAi}

w^*; P{UAS-scrib.RNAi}7L

Selected Drosophila classical alleles

Allele

Allele class

Mutagen

Publicly Available Stocks

Raf⁹²⁶

loss of function allele

ethyl methanesulfonate

Raf^raf-1

amorphic allele - genetic evidence

nitrosomethyl urea

Raf^XS-2541

X ray

Raf^raf-2

loss of function allele

Raf¹

amorphic allele - genetic evidence

X ray

Raf^400B8

amorphic allele - genetic evidence

1,2-dichloroethane

Raf¹¹

amorphic allele - genetic evidence

spontaneous

Raf¹¹/FM6, l(1)FMa¹/Dp(1;Y)Bar^Sw⁺y⁺

Raf^C2Z2

amorphic allele - genetic evidence

ethyl methanesulfonate

Raf⁷

loss of function allele

ethyl methanesulfonate

Raf⁷/FM7a

Raf¹²

hycanthon methanesulfonate

y¹ w^a Raf¹²/FM6, wⁱ Myc⁺

Raf¹⁰⁷

amorphic allele - genetic evidence

ethyl methanesulfonate

Raf⁶

amorphic allele - genetic evidence

ethyl methanesulfonate

Raf^X1

amorphic allele - genetic evidence

X ray

Raf⁵

amorphic allele - genetic evidence

ethyl methanesulfonate

scrib^j7B3

P-element activity

y^d2 w¹¹¹⁸ P{ey-FLP.N}2 P{5xglBS-lacZ.38-1}TPN1; P{neoFRT}82B P{lacW}scrib^j7B3/TM6B, P{Car20y}TPN1, Tb¹

scrib^ird15

loss of function allele

ethyl methanesulfonate

scrib¹

loss of function allele

ethyl methanesulfonate

scrib⁶⁷³

loss of function allele

ethyl methanesulfonate

Dp(1;Y)Bar^S; scrib⁶⁷³ e¹/TM3, Ser¹

References (8)

Report Sections

Open Close